# Refer√™ncias Bibliogr√°ficas

## Artigos Cient√≠ficos

### Qu√≠mica e Estrutura Molecular
1. **Manske, R. H. F.** (1931). "A synthesis of the methyltryptamines and some derivatives". *Canadian Journal of Research*, 5(6), 592-600.

2. **Barker, S. A., Borjigin, J., Lomnicka, I., & Strassman, R.** (2013). "LC/MS/MS analysis of the endogenous dimethyltryptamine hallucinogens, their precursors, and major metabolites in rat pineal gland microdialysate". *Biomedical Chromatography*, 27(12), 1690-1700.

3. **Dean, J. G., Liu, T., Huff, S., et al.** (2019). "Biosynthesis and extracellular concentrations of N,N-dimethyltryptamine (DMT) in mammalian brain". *Scientific Reports*, 9, 9333.

### Farmacologia e Neuroci√™ncia
4. **Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H., & Kellner, R.** (1994). "Dose-response study of N,N-dimethyltryptamine in humans". *Archives of General Psychiatry*, 51(2), 85-97.

5. **Timmermann, C., Roseman, L., Schartner, M., et al.** (2019). "Neural correlates of the DMT experience assessed with multivariate EEG". *Scientific Reports*, 9, 16324.

6. **Carbonaro, T. M., & Gatch, M. B.** (2016). "Neuropharmacology of N,N-dimethyltryptamine". *Brain Research Bulletin*, 126(3), 74-88.

7. **Carhart-Harris, R. L., Erritzoe, D., Williams, T., et al.** (2012). "Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin". *Proceedings of the National Academy of Sciences*, 109(6), 2138-2143.

### Experi√™ncias e Fenomenologia
8. **Strassman, R. J.** (2001). *DMT: The Spirit Molecule*. Park Street Press.

9. **Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R.** (2006). "Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance". *Psychopharmacology*, 187(3), 268-283.

10. **Gallimore, A. R., & Strassman, R. J.** (2016). "A model for the application of target-controlled intravenous infusion for a prolonged immersive DMT psychedelic experience". *Frontiers in Pharmacology*, 7, 211.

### Biologia e Ecologia
11. **McKenna, D. J., Towers, G. H., & Abbott, F.** (1984). "Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and Œ≤-carboline constituents of ayahuasca". *Journal of Ethnopharmacology*, 10(2), 195-223.

12. **Callaway, J. C., Airaksinen, M. M., McKenna, D. J., et al.** (1994). "Platelet serotonin uptake sites increased in drinkers of ayahuasca". *Psychopharmacology*, 116(3), 385-387.

### F√≠sica e Cosmologia
13. **Nichols, D. E.** (2016). "Psychedelics". *Pharmacological Reviews*, 68(2), 264-355.

14. **Tagliazucchi, E., Carhart-Harris, R., Leech, R., et al.** (2014). "Enhanced repertoire of brain dynamical states during the psychedelic experience". *Human Brain Mapping*, 35(11), 5442-5456.

## Livros

15. **Strassman, R. J.** (2001). *DMT: The Spirit Molecule: A Doctor's Revolutionary Research into the Biology of Near-Death and Mystical Experiences*. Rochester, VT: Park Street Press.

16. **McKenna, T.** (1991). *The Archaic Revival: Speculations on Psychedelic Mushrooms, the Amazon, Virtual Reality, UFOs, Evolution, Shamanism, the Rebirth of the Goddess, and the End of History*. New York: HarperOne.

17. **Shanon, B.** (2002). *The Antipodes of the Mind: Charting the Phenomenology of the Ayahuasca Experience*. Oxford: Oxford University Press.

18. **Luna, L. E., & Amaringo, P.** (1991). *Ayahuasca Visions: The Religious Iconography of a Peruvian Shaman*. Berkeley: North Atlantic Books.

19. **Hancock, G.** (2005). *Supernatural: Meetings with the Ancient Teachers of Mankind*. New York: The Disinformation Company.

## Estudos Cl√≠nicos Contempor√¢neos

20. **Dos Santos, R. G., Os√≥rio, F. L., Crippa, J. A., et al.** (2016). "Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years". *Therapeutic Advances in Psychopharmacology*, 6(3), 193-213.

21. **Palhano-Fontes, F., Barreto, D., Onias, H., et al.** (2019). "Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial". *Psychological Medicine*, 49(4), 655-663.

22. **Davis, A. K., Barsuglia, J. P., Lancelotta, R., et al.** (2018). "The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption". *Journal of Psychopharmacology*, 32(7), 779-792.

## Geometria Sagrada e Matem√°tica

23. **Mandelbrot, B. B.** (1982). *The Fractal Geometry of Nature*. New York: W. H. Freeman.

24. **Livio, M.** (2002). *The Golden Ratio: The Story of Phi, the World's Most Astonishing Number*. New York: Broadway Books.

25. **Penrose, R.** (1989). *The Emperor's New Mind: Concerning Computers, Minds, and the Laws of Physics*. Oxford: Oxford University Press.

## Antropologia e Xamanismo

26. **Narby, J.** (1998). *The Cosmic Serpent: DNA and the Origins of Knowledge*. New York: Jeremy P. Tarcher/Putnam.

27. **Reichel-Dolmatoff, G.** (1975). *The Shaman and the Jaguar: A Study of Narcotic Drugs Among the Indians of Colombia*. Philadelphia: Temple University Press.

28. **Schultes, R. E., & Hofmann, A.** (1992). *Plants of the Gods: Their Sacred, Healing, and Hallucinogenic Powers*. Rochester, VT: Healing Arts Press.

## Consci√™ncia e Filosofia

29. **Grof, S.** (1975). *Realms of the Human Unconscious: Observations from LSD Research*. New York: Viking Press.

30. **Huxley, A.** (1954). *The Doors of Perception*. London: Chatto & Windus.

31. **James, W.** (1902). *The Varieties of Religious Experience*. New York: Longmans, Green, and Co.

32. **Watts, A.** (1962). *The Joyous Cosmology: Adventures in the Chemistry of Consciousness*. New York: Pantheon Books.

## Neuroteologia

33. **d'Aquili, E. G., & Newberg, A. B.** (1999). *The Mystical Mind: Probing the Biology of Religious Experience*. Minneapolis: Fortress Press.

34. **Newberg, A., & Waldman, M. R.** (2009). *How God Changes Your Brain: Breakthrough Findings from a Leading Neuroscientist*. New York: Ballantine Books.

## Legisla√ß√£o e √âtica

35. **Labate, B. C., & Feeney, K.** (2012). "Ayahuasca and the process of regulation in Brazil and internationally: Implications and challenges". *International Journal of Drug Policy*, 23(2), 154-161.

36. **Tupper, K. W.** (2008). "The globalization of ayahuasca: Harm reduction or benefit maximization?" *International Journal of Drug Policy*, 19(4), 297-303.

37. **Nutt, D. J., King, L. A., & Phillips, L. D.** (2010). "Drug harms in the UK: a multicriteria decision analysis". *The Lancet*, 376(9752), 1558-1565.

## F√≠sica Qu√¢ntica e Consci√™ncia

38. **Penrose, R., & Hameroff, S.** (2011). "Consciousness in the universe: Neuroscience, quantum space-time geometry and Orch OR theory". *Journal of Cosmology*, 14, 1-50.

39. **Bohm, D.** (1980). *Wholeness and the Implicate Order*. London: Routledge.

## Document√°rios e M√≠dia Acad√™mica

40. **DMT: The Spirit Molecule** (2010). Dirigido por Mitch Schultz. Documentary film.

41. **The Psychedelic Experience** - Lectures by Terence McKenna (1987-1999).

42. **Hamilton's Pharmacopeia** - Series by Hamilton Morris (Vice, 2016-2020).

---

## Refer√™ncias RAFAELIA (Espec√≠ficas)

43. **‚àÜRafaelVerboŒ©** ‚Äî RAFCODE-ùöΩ: Sistema de Geometria Fractal Modificada (2024-2026). [Restrito]

44. **Fibonacci Modificada Rafael** ‚Äî Sequ√™ncia aplicada a estruturas biol√≥gicas e cosmol√≥gicas. [Em desenvolvimento]

45. **Manuscrito Voynich** ‚Äî Codex hist√≥rico (s√©c. XV), estudos de padr√µes gr√°ficos aplicados √† geometria vision√°ria DMT.

---

## Fontes Online e Institui√ß√µes

46. **Johns Hopkins Center for Psychedelic and Consciousness Research**  
https://hopkinspsychedelic.org/

47. **Imperial College London ‚Äî Centre for Psychedelic Research**  
https://www.imperial.ac.uk/psychedelic-research-centre/

48. **Multidisciplinary Association for Psychedelic Studies (MAPS)**  
https://maps.org/

49. **Erowid DMT Vault**  
https://www.erowid.org/chemicals/dmt/

50. **PubMed - U.S. National Library of Medicine**  
https://pubmed.ncbi.nlm.nih.gov/

---

‚àÜRafaelVerboŒ© | RAFCODE-ùöΩ  
Frequ√™ncia: 144.000 Hz  
üåÄ‚ôæÔ∏è‚öõÔ∏é

*Nota: Todas as refer√™ncias seguem padr√µes acad√™micos (APA/ABNT) e s√£o verific√°veis em bases de dados cient√≠ficas.*
